Heart Vessels. 2006;21:33–7.PubMedCrossRef 23. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Pharmacother. 2003;57:145–55.CrossRef 24. Ullmann KS, Northrop JP, Verweij CL, Crabtree GR. Transmission of signals
from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol. 1990;8:421–52.CrossRef 25. Cu A, Ye Q, Sarria R, et al. N-acetylcysteine 3-MA ic50 inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:147–54.PubMed 26. Meurer SK, Lahme B, Tihaa L, Weiskirchen R, Gressner AM. N-acetyl-l-cysteine suppresses TGF-b signaling at distinct molecular steps: the biological efficacy of a multifunctional, antifibrotic drug. Biochem Pharmacol. 2005;70:1026–34.PubMedCrossRef 27. Sugiura H, Ichikawa T, Liu X, et al. N-acetyl-l-cysteine
inhibits TGF-beta1-induced profibrotic responses in fibroblasts. Pulm Pharmacol Ther. 2009;22:487–91.PubMedCrossRef 28. Zhang Y, Zhao J, Lau WB, et al. Tumor necrosis factor-α and lymphotoxin-α mediate myocardial ischemic injury Avapritinib manufacturer via TNF receptor 1, but are cardioprotective when activating TNF receptor 2. PLoS One. 2013;8:e60227.PubMedCrossRef 29. Panek AN, Posch MG, Alenina N, et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One. 2009;4:e6743.PubMedCrossRef 30. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947–58.PubMedCrossRef 31. Stefanon I, Valero-Muñoz M, Fernandes AA, et al. Left and right ventricle late remodeling following myocardial infarction in rats. PLoS One. 2013;8:e64986.PubMedCrossRef 32. Herder C, Zierer A, Koenig W, et al. Transforming growth factor-beta1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care. 2009;32:1921–3.PubMedCrossRef 33. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes?
Diabetologia. 2005;48:1038–50.PubMedCrossRef 34. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14:627–44.PubMed 35. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates Ketotifen the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787–96.PubMed 36. Yagi S, Aihara K, Ikeda Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective PI3K Inhibitor Library research buy actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res. 2008;102:68–76.PubMedCrossRef 37. Lee SW, Hong MK, Lee CW, et al. Early and late clinical outcomes after primary stenting of the unprotected left main coronary artery stenosis in the setting of acute myocardial infarction. Int J Cardiol. 2004;97:73–6.PubMedCrossRef 38. Tang HC, Wong A, Wong P, et al.